Effectiveness and safety of dulaglutide 0.75 mg versus insulin glargine by starting blood sugar levels in Japanese patients with type 2 diabetes

Dulaglutide 0.75 mg resulted in a statistically significantly greater reduction in HbA1c compared to insulin glargine after 26 weeks in patients with type 2 diabetes.

• Patients with baseline HbA1c ≤8.5% experienced a reduction of -1.27% with dulaglutide versus -0.72% with glargine.
• In patients with baseline HbA1c >8.5%, dulaglutide led to a reduction of -2.04%, compared to -1.47% with glargine.
• Dulaglutide treatment was associated with weight loss, while glargine treatment resulted in weight gain in both HbA1c subgroups.
• Both treatment groups showed similar reductions in fasting blood glucose, but dulaglutide provided a greater reduction in postprandial blood glucose.
• While dulaglutide increased mild gastrointestinal adverse events, these were generally well tolerated.
• Dulaglutide was associated with a lower incidence of hypoglycemia compared to glargine.

Simplified